Rapid responses are electronic comments to the editor. They enable our users
to debate issues raised in articles published on bmj.com. A rapid response
is first posted online. If you need the URL (web address) of an individual
response, simply click on the response headline and copy the URL from the
browser window. A proportion of responses will, after editing, be published
online and in the print journal as letters, which are indexed in PubMed.
Rapid responses are not indexed in PubMed and they are not journal articles.
The BMJ reserves the right to remove responses which are being
wilfully misrepresented as published articles or when it is brought to our
attention that a response spreads misinformation.
From March 2022, the word limit for rapid responses will be 600 words not
including references and author details. We will no longer post responses
that exceed this limit.
The word limit for letters selected from posted responses remains 300 words.
In the news item, 'Valproate ban for women of childbearing age', it is noted that valproate is an anti-epileptic drug (1). What is not alluded to is Valproate's role in the treatment of bipolar disorder (2).
Is the ban on Valproate a general one? Or does the ban not extend to Valproate for bipolar illness during pregnancy?
The Maudsley Guidelines comment: 'Although 1 in 20 women of child-bearing age who are in long-term contact with mental health services are prescribed mood-stabilising drugs, awareness of the teratogenic potential of these drugs amongst psychiatrists is low' (3).
Carbamazepine is similarly employed for both epilepsy and mental illness. Carbamazepine too is linked to spina bifida and other problems in babies.
Is there no pregnancy ban on Carbamazepine?
Lithium, the archetypal mood stabilizer, is connected also with difficulties in foetal development.
REFERENCES:
(1) Valproate ban for women of child-bearing age. BMJ2018; 361:k1823. Gareth Iacobucci. 5 May, 2918.
(2) The Maudsley Prescribing Guidelines. David Taylor, Carol Paton, Shitij Kapur. Informa healthcare. 2009.
The problem extends beyond Valproate and epilepsy
In the news item, 'Valproate ban for women of childbearing age', it is noted that valproate is an anti-epileptic drug (1). What is not alluded to is Valproate's role in the treatment of bipolar disorder (2).
Is the ban on Valproate a general one? Or does the ban not extend to Valproate for bipolar illness during pregnancy?
The Maudsley Guidelines comment: 'Although 1 in 20 women of child-bearing age who are in long-term contact with mental health services are prescribed mood-stabilising drugs, awareness of the teratogenic potential of these drugs amongst psychiatrists is low' (3).
Carbamazepine is similarly employed for both epilepsy and mental illness. Carbamazepine too is linked to spina bifida and other problems in babies.
Is there no pregnancy ban on Carbamazepine?
Lithium, the archetypal mood stabilizer, is connected also with difficulties in foetal development.
REFERENCES:
(1) Valproate ban for women of child-bearing age. BMJ2018; 361:k1823. Gareth Iacobucci. 5 May, 2918.
(2) The Maudsley Prescribing Guidelines. David Taylor, Carol Paton, Shitij Kapur. Informa healthcare. 2009.
(3) Ibid. Pg. 351.
(4) Ibid. Pgs. 350-351.
Competing interests: No competing interests